Affimed NV (NAS:AFMD)
$ 3.85 0.02 (0.52%) Market Cap: 60.37 Mil Enterprise Value: 37.91 Mil PE Ratio: 0 PB Ratio: 1.95 GF Score: 43/100

Affimed NV Investor Day Transcript

Dec 09, 2021 / 01:30PM GMT
Release Date Price: $62.5 (-8.49%)
Operator

Good day, and thank you for standing by. Welcome to the Affimed Financial Community Update Call. (Operator Instructions) Please be advised today's conference is being recorded. (Operator Instructions)

I'd now like to hand the conference over to Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, Liz. I'd like to welcome and thank you all for joining us today to discuss the updated data from our investigator-sponsored clinical trial at MD Anderson Cancer Center. As you may remember, we released these data on November 22.

Before we begin, I'd like to bring your attention to the fact that we issued a press release earlier today that includes updates to that data that will be discussed on the call today. This press release and a copy of today's presentation may be found on our website. Investors listening in on the webcast are also able to download the presentation from there.

Before we start, I would like to quickly go through the safe harbor statement. Today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot